2022 World Conference on Lung Cancer (ePosters)-EP08.01-032. Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study

EP08.01-032. Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study

Back to course

Pdf Summary

In this study, researchers aimed to evaluate the effectiveness and safety of combining the PD-1/PD-L1 inhibitor sintilimab with the anti-angiogenesis drug anlotinib in non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations. Uncommon EGFR mutations typically have worse outcomes compared to classic EGFR mutations. Twenty-one NSCLC patients with rare EGFR mutations were enrolled in the study after receiving previous treatments. The patients received a combination of sintilimab and anlotinib, and the primary endpoint was the objective response rate (ORR). <br />At the time of data analysis, the median follow-up period was 19.0 months. Among the enrolled patients, twelve had EGFR Ex20ins mutations while the remaining nine had other uncommon EGFR mutations such as L861Q, G719A, and G709T. The median progression-free survival (PFS) for patients with uncommon EGFR mutations was 7.0 months, and the 6-month PFS rate was 57.1%. The objective response rate was 38.1%, and the disease control rate was 85.7%. Interestingly, patients with EGFR Ex20ins mutations had similar PFS compared to those with other mutation patterns. <br />The commonly observed grade 3 or greater treatment-related adverse events included hypertension, immune-related pneumonitis, and hand-foot syndrome. However, overall, the combination of sintilimab and anlotinib did not result in significant safety concerns. <br />In conclusion, the combination of sintilimab and anlotinib demonstrated durable efficacy and good tolerability in NSCLC patients with uncommon EGFR mutations. The results indicate that this chemo-free strategy may be a promising treatment option for these patients, but further research is needed to confirm these findings.

Asset Subtitle

Yun Fan

Meta Tag

Speaker Yun Fan

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

PD-1/PD-L1 inhibitor

sintilimab

anti-angiogenesis drug

anlotinib

non-small cell lung cancer

NSCLC

uncommon EGFR mutations

objective response rate

progression-free survival

treatment-related adverse events